Zobrazeno 1 - 10
of 174
pro vyhledávání: '"MAYA LODISH"'
Autor:
Kannan Kasturi, Lucas Fernandes, Martha Quezado, Mary Eid, Leigh Marcus, Prashant Chittiboina, Mark Rappaport, Constantine A. Stratakis, Brigitte Widemann, Maya Lodish
Publikováno v:
Journal of Clinical and Translational Endocrinology Case Reports, Vol 4, Iss , Pp 1-4 (2017)
Context: Multiple endocrine neoplasia type 2B (MEN2B) is a rare autosomal-dominant cancer syndrome characterized in part by metastatic medullary thyroid cancer (MTC) and pheochromocytoma. Cushing disease is a rare cause of endogenous hypercortisolism
Externí odkaz:
https://doaj.org/article/0eaa20c40e5549579e5072c8c9bfaaad
Autor:
Namrata Patel-Sanchez, Emily Perito, Patrika Tsai, Marissa Raymond-Flesch, Maya Lodish, Monika Sarkar
Publikováno v:
J Pediatr Endocrinol Metab
Objectives Polycystic ovary syndrome (PCOS) increases non-alcoholic fatty liver disease (NAFLD) risk and severity in adults, but data in adolescents with diverse backgrounds are limited. We evaluated NAFLD prevalence and characterized NAFLD risk fact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc56c34045df96aa10e3f51e4aa9f456
https://doi.org/10.1515/jpem-2022-0527
https://doi.org/10.1515/jpem-2022-0527
Autor:
Crystal L. Mackall, Howard Streicher, Jedd D. Wolchok, Rachel Bishop, Maya Lodish, Cindy Delbrook, Donna Bernstein, Carlos Rodriguez-Galindo, Leonard H. Wexler, Kristin Baird, Matthew Wright, Melinda S. Merchant
Absolute numbers of CD3+ and CD4+ HLA-DR+ activated T cells increase at day 21 and day 42 following ipilimumab infusion.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f31e88646c1faf0dadfa6c7abdd5333
https://doi.org/10.1158/1078-0432.22459578
https://doi.org/10.1158/1078-0432.22459578
Autor:
Brigitte C. Widemann, Jack F. Shern, John W. Glod, Paul S. Meltzer, Maria J. Merino, Frank M. Balis, Elizabeth Fox, Oxana Kapustina, Steven G. Waguespack, Maya Lodish, Seth M. Steinberg, Eva Dombi, Claudia Derse-Anthony, Haiyan Lei, Yuelin Zhu, Srivandana Akshintala, Ira L. Kraft
Legends for all included Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::401e3632a772a57ba85735bffe03f137
https://doi.org/10.1158/1078-0432.22464179
https://doi.org/10.1158/1078-0432.22464179
Autor:
Brigitte C. Widemann, Jack F. Shern, John W. Glod, Paul S. Meltzer, Maria J. Merino, Frank M. Balis, Elizabeth Fox, Oxana Kapustina, Steven G. Waguespack, Maya Lodish, Seth M. Steinberg, Eva Dombi, Claudia Derse-Anthony, Haiyan Lei, Yuelin Zhu, Srivandana Akshintala, Ira L. Kraft
Heat map of cell cycle gene expression. Gene expression was normalized and compared between the primary MTC, metastasis one, and metastasis two lesions from the whole transcriptome RNA-seq data. Purple indicates lower and yellow indicates higher expr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d6248f3a4f6a5680d83c0d84ae52748
https://doi.org/10.1158/1078-0432.22464182
https://doi.org/10.1158/1078-0432.22464182
Autor:
Brigitte C. Widemann, Jack F. Shern, John W. Glod, Paul S. Meltzer, Maria J. Merino, Frank M. Balis, Elizabeth Fox, Oxana Kapustina, Steven G. Waguespack, Maya Lodish, Seth M. Steinberg, Eva Dombi, Claudia Derse-Anthony, Haiyan Lei, Yuelin Zhu, Srivandana Akshintala, Ira L. Kraft
Weight-for-age and height-for-age growth curves. Male patient weights (A), heights (B) and female patient weights (C), and heights (D) were monitored during the follow up period. Patient weight-for-age and height-for-age values were compared to U.S.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ec07263c4329612840f782bb5fe4d8c
https://doi.org/10.1158/1078-0432.22464185.v1
https://doi.org/10.1158/1078-0432.22464185.v1
Autor:
Brigitte C. Widemann, Jack F. Shern, John W. Glod, Paul S. Meltzer, Maria J. Merino, Frank M. Balis, Elizabeth Fox, Oxana Kapustina, Steven G. Waguespack, Maya Lodish, Seth M. Steinberg, Eva Dombi, Claudia Derse-Anthony, Haiyan Lei, Yuelin Zhu, Srivandana Akshintala, Ira L. Kraft
Doubling time of calcitonin and CEA for patient #12 was suggestive of progressive disease. Patient #12 experienced best response 434 days after starting vandetanib, with stable lesions in the thyroid bed (showed on T2-weighted MRI of the neck, A) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19839df255ead36a5ece83747a68a1df
https://doi.org/10.1158/1078-0432.22464188
https://doi.org/10.1158/1078-0432.22464188
Autor:
Brigitte C. Widemann, Jack F. Shern, John W. Glod, Paul S. Meltzer, Maria J. Merino, Frank M. Balis, Elizabeth Fox, Oxana Kapustina, Steven G. Waguespack, Maya Lodish, Seth M. Steinberg, Eva Dombi, Claudia Derse-Anthony, Haiyan Lei, Yuelin Zhu, Srivandana Akshintala, Ira L. Kraft
Purpose: Vandetanib is well-tolerated in patients with advanced medullary thyroid carcinoma (MTC). Long-term outcomes and mechanisms of MTC progression have not been reported previously.Experimental Design: We monitored toxicities and disease status
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::549078e1f12e692d01fc00ebd014fd07
https://doi.org/10.1158/1078-0432.c.6525638
https://doi.org/10.1158/1078-0432.c.6525638
Autor:
Frank M. Balis, Samuel A. Wells, Seth M. Steinberg, Eva Dombi, Maya Lodish, Maria J. Merino, Patricia O. Whitcomb, Alberta Aikin, Leigh Marcus, Meredith K. Chuk, Brigitte C. Widemann, Elizabeth Fox
Purpose: Medullary thyroid carcinoma (MTC) is a manifestation of multiple endocrine neoplasia type 2 (MEN2) syndromes caused by germline, activating mutations in the RET (REarranged during Transfection) proto-oncogene. Vandetanib, a VEGF and EGF rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044bad50076cee5828c0380bdf133ec6
https://doi.org/10.1158/1078-0432.c.6521100
https://doi.org/10.1158/1078-0432.c.6521100
Autor:
Crystal L. Mackall, Howard Streicher, Jedd D. Wolchok, Rachel Bishop, Maya Lodish, Cindy Delbrook, Donna Bernstein, Carlos Rodriguez-Galindo, Leonard H. Wexler, Kristin Baird, Matthew Wright, Melinda S. Merchant
Purpose: Ipilimumab is a first-in-class immune checkpoint inhibitor approved for treatment of metastatic melanoma but not studied in children until this phase I protocol.Experimental Design: This study examined safety, pharmacokinetics, and immunogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d91f2e7b03e2c507370baa54370d861
https://doi.org/10.1158/1078-0432.c.6524250.v1
https://doi.org/10.1158/1078-0432.c.6524250.v1